Submit Deal

AMICUS THERAPEUTICS

HQ - Cranbury, NJ

Summary

Amicus Therapeutics is a biotechnology company developing therapies for Fabry disease and Pompe disease.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 4.46 B

Avg. Deal Size£ 1.11 B

Market Context

Subsidiaries

AMICUS THERAPEUTICS (GENE THERAPY BUSINESS)

1 transaction

Senior Management

Bradley Campbell
President and CEO
John F. Crowley
Chairman and CEO
Simon Harford
CFO

Sort

29 Sep 2021|United States|Biotechnology

Target: AMICUS THERAPEUTICS (GENE THERAPY BUSINESS)

Bidder: ARYA SCIENCES ACQUISITION CORP IV

9 Service Providers

4 Bidder | 5 Vendor

25 Dealmakers

10 Bidder | 15 Vendor

£ 440 M

Value

20 Sep 2018|United States|Biotechnology

Target: CELENEX

Bidder: AMICUS THERAPEUTICS

6 Service Providers

3 Target | 3 Bidder

8 Dealmakers

1 Target | 7 Bidder

£ 76 M

Value

02 Oct 2023|United States|Biotechnology

Target: AMICUS THERAPEUTICS

Bidder: BLACKSTONE GROUP INC

2 Service Providers

1 Target | 1 Bidder

7 Dealmakers

4 Target | 3 Bidder

£ 352 M

Value

19 Dec 2025|United States|Biotechnology

Target: AMICUS THERAPEUTICS

Bidder: BIOMARIN PHARMACEUTICAL INC

11 Service Providers

6 Target | 5 Bidder

82 Dealmakers

66 Target | 17 Bidder

£ 3.59 B

Value